FY2026 EPS Estimates for Insmed Reduced by Leerink Partnrs

Insmed Incorporated (NASDAQ:INSM) – Research analysts at Leerink Partnrs decreased their FY2026 earnings per share (EPS) estimates for Insmed in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will post earnings of ($3.39) per share for the year, down from their prior estimate of ($3.32). The consensus estimate for Insmed’s current full-year earnings is ($5.44) per share.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to the consensus estimate of $93.36 million. During the same period in the previous year, the firm earned ($1.10) earnings per share. The company’s revenue for the quarter was up 18.1% compared to the same quarter last year.

A number of other analysts have also recently commented on INSM. JPMorgan Chase & Co. boosted their price objective on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Truist Financial restated a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Finally, Bank of America boosted their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Trading Down 0.8 %

Shares of NASDAQ:INSM opened at $77.84 on Wednesday. Insmed has a 12-month low of $21.92 and a 12-month high of $80.53. The company has a market capitalization of $13.93 billion, a PE ratio of -14.03 and a beta of 1.12. The business has a 50 day moving average of $71.48 and a two-hundred day moving average of $72.80. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insider Buying and Selling at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 3,344 shares of the company’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total value of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares in the company, valued at $6,773,307.06. This represents a 3.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50. Following the completion of the transaction, the chief executive officer now directly owns 384,960 shares in the company, valued at approximately $26,912,553.60. This trade represents a 4.64 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 104,740 shares of company stock worth $7,161,294 in the last three months. 4.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in shares of Insmed by 4.7% in the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock valued at $278,432,000 after purchasing an additional 172,664 shares during the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Insmed in the 2nd quarter valued at $237,076,000. Principal Financial Group Inc. lifted its stake in shares of Insmed by 12.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after purchasing an additional 214,130 shares during the last quarter. Clearbridge Investments LLC lifted its stake in shares of Insmed by 76.8% in the 2nd quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock valued at $110,212,000 after purchasing an additional 714,539 shares during the last quarter. Finally, Vestal Point Capital LP lifted its stake in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after purchasing an additional 850,000 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.